Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Post by Steveminon Feb 11, 2021 10:14am
155 Views
Post# 32536911

Adams

AdamsInmed has been stagnate and trending down for 3 years. They have no substantive news of their own that would lead to any share price appreciation.
Usually companies - even if they are small and unproven - will move with their sector due to the law of association (as we saw with Inmed in early 2018).

Once a company decouples from its sector mates and no longer moves in association, that is usually indicative of a systemic and problematic issue within the company. The "market" has a way of identifying this and treating the company accordingly.

This is what we are seeing with Inmed. Adams very well could be a very nice guy, but he is woefully failing as Inmed's CEO. The pace at which this company is progressing is excruciatingly slow. In June, he will have been CEO for 5 years. 5 Years and the sp is trading basically where it was when he took over in 2016. This is unacceptable under any circumstances but for Inmed to be in a sector (which arguably will be the biggest and most important we have seen in decades) is unforgivable.

#timetoreplaceadams


<< Previous
Bullboard Posts
Next >>